Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“3+7 and Ivosidenib in newly diagnosed IDH1m AML Conclusion
IVO-based induction, consolidation, and maintenance produced durable remissions, acceptable safety, and strong long-term survival.
High response rates and reliable blood count normalization were observed, with nearly half of patients able to proceed to transplant. Outcomes were similar across treatment arms, and the regimen is now being tested in a phase 3 randomized trial.”
You can also read:
